Key result
Genetic analysis of 8 Iranian families with dysferlinopathy identified two novel DYSF mutations and suggested a founder mutation in two families of the same ethnicity.
Why the study?
There are few reports on Iranian dysferlinopathy patients, prompting an effort to identify DYSF mutations in affected individuals from Iran.
Observational (n=8)
Genetic analysis of Iranian patients with dysferlinopathy identified novel DYSF mutations and a potential founder effect, which can aid in accurate diagnosis and prevent misdiagnosis of myositis.
May inform local genetic counseling; extends DYSF variant spectrum but leaves founder effect confirmation open.
BACKGROUND: Dysferlinopathies are a group of autosomal recessive limb-girdle muscular dystrophies (LGMDs) caused by mutations in DYSF (#603,009). This gene encodes a transmembrane protein called dysferlin. Since there are few reports on Iranian dysferlinopathy patients, we tried to identify the DYSF mutations in affected individuals of Iran. METHODS: Eight unrelated Iranian families have been selected for this study. Sanger sequencing followed by haplotype analysis was performed to identify individual variations in DYSF sequence. Identified variants were analyzed, and their pathogenicity was interpreted according to the recommendations of the American College of Medical Genetics and Genomics. RESULTS: We identified two new mutations in DYSF, the first one is a nonsense mutation c.2419C > T (p.Gln807*), which eliminates downstream part of the protein. Another novel mutation is c. (1,053 + 1_1,054-1)_(1,397 + 1_1,398-1)del, which causes deletion of the DNA segment from exon 12 to exon 15. CONCLUSION: Two of the other six families are from the same ethnicity and share the same mutation and haplotype patterns, suggesting a founder mutation. Genetic analysis of dysferlinopathy can prevent a wrong diagnosis of myositis for these patients.
No takes yet. Share an insight, caveat, or question.
Mojbafan et al. (2019) conducted an observational in Limb-girdle muscular dystrophy type 2B (dysferlinopathies) (n=8). Sanger sequencing and haplotype analysis was evaluated on Identification of DYSF mutations. Genetic analysis of 8 Iranian families with dysferlinopathy identified two novel DYSF mutations and suggested a founder mutation in two families of the same ethnicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: